clofarabine pediatric ALL
Selected indexed studies
- Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. (Br J Haematol, 2024) [PMID:38501389]
- Clofarabine. (Nat Rev Drug Discov, 2005) [PMID:15962525]
- Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL. (RSC Adv, 2022) [PMID:36425201]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clofarabine. (2005) pubmed
- Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. (2024) pubmed
- Clofarabine in leukemia. (2010) pubmed
- Clofarabine. (2005) pubmed
- Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL. (2022) pubmed
- Clofarabine in pediatric acute leukemia: current findings and issues. (2012) pubmed
- Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation? (2023) pubmed
- Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting. (2023) pubmed
- The effects of clofarabine in ALL inhibition through DNA methylation regulation. (2020) pubmed
- Successful clofarabine desensitization in a pediatric patient with acute myeloid leukemia. (2022) pubmed